CA2468935C - Adjuvanted antigenic meningococcal compositions - Google Patents

Adjuvanted antigenic meningococcal compositions Download PDF

Info

Publication number
CA2468935C
CA2468935C CA2468935A CA2468935A CA2468935C CA 2468935 C CA2468935 C CA 2468935C CA 2468935 A CA2468935 A CA 2468935A CA 2468935 A CA2468935 A CA 2468935A CA 2468935 C CA2468935 C CA 2468935C
Authority
CA
Canada
Prior art keywords
antigen
composition
protein
ref
patent application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2468935A
Other languages
English (en)
French (fr)
Other versions
CA2468935A1 (en
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of CA2468935A1 publication Critical patent/CA2468935A1/en
Application granted granted Critical
Publication of CA2468935C publication Critical patent/CA2468935C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2468935A 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions Expired - Fee Related CA2468935C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0129007.1 2001-12-04
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (2)

Publication Number Publication Date
CA2468935A1 CA2468935A1 (en) 2003-06-12
CA2468935C true CA2468935C (en) 2013-02-05

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2468935A Expired - Fee Related CA2468935C (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Country Status (11)

Country Link
US (2) US20060008476A1 (enExample)
EP (1) EP1448230B1 (enExample)
JP (2) JP4414226B2 (enExample)
AP (1) AP2004003074A0 (enExample)
AT (1) ATE485055T1 (enExample)
AU (1) AU2002353417A1 (enExample)
CA (1) CA2468935C (enExample)
CY (1) CY1111114T1 (enExample)
DE (1) DE60238075D1 (enExample)
GB (1) GB0129007D0 (enExample)
WO (1) WO2003047619A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
PT1790660E (pt) * 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
IL159210A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
RU2378008C2 (ru) * 2002-05-14 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2540896C (en) * 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2012059593A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
MX2021007539A (es) 2018-12-21 2021-09-21 Univ Griffith Composiciones, metodos y usos para provocar una respuesta inmune.
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
US20220348645A1 (en) * 2019-10-01 2022-11-03 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69841807D1 (de) * 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
DE69941567D1 (de) * 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
DK1117435T3 (da) * 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
JP2009155344A (ja) 2009-07-16
WO2003047619A3 (en) 2003-10-23
US20060008476A1 (en) 2006-01-12
AP2004003074A0 (en) 2004-06-30
JP2005511662A (ja) 2005-04-28
EP1448230A2 (en) 2004-08-25
CY1111114T1 (el) 2015-06-11
CA2468935A1 (en) 2003-06-12
ATE485055T1 (de) 2010-11-15
WO2003047619A2 (en) 2003-06-12
AU2002353417A1 (en) 2003-06-17
EP1448230B1 (en) 2010-10-20
GB0129007D0 (en) 2002-01-23
US20100233205A1 (en) 2010-09-16
JP4414226B2 (ja) 2010-02-10
DE60238075D1 (de) 2010-12-02

Similar Documents

Publication Publication Date Title
CA2468935C (en) Adjuvanted antigenic meningococcal compositions
EP2327719B1 (en) Hybrid and tandem expression of neisserial proteins
CA2452720C (en) Vaccines comprising aluminium adjuvants and histidine
US20050158334A1 (en) Vaccines comprising aluminium adjuvants and histidine
AU2002339217A1 (en) Hybrid and tandem expression of Neisserial proteins
AU2002330681A1 (en) Vaccines comprising aluminium adjuvants and histidine
AU2012202488B2 (en) Hybrid and tandem expression of Neisserial proteins
AU2014201962B2 (en) Hybrid and tandem expression of Neisserial proteins

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141204